1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study.
Abstract | OBJECTIVE: During the last decades, management of intertriginous psoriasis (IP) has been unsatisfactory because of the adverse effects associated with long-term corticosteroid application and the lack of alternatives. Recently, both pimecrolimus and tacrolimus have been investigated for this indication and shown to be safe and effective. So far, to our knowledge, a comparison of one of these drugs with standard regimens for IP has not been performed. DESIGN: SETTING: Dermatologic hospital at Ruhr University of Bochum. PATIENTS: Eighty adults with IP. INTERVENTIONS: MAIN OUTCOME MEASURES: Mean reduction of the Modified Psoriasis Area and Severity Index (M-PASI) score after 28 days of treatment was considered the primary outcome measure, which was analyzed on an intention-to-treat basis. The secondary outcome was a visual analog scale score for itching. RESULTS: CONCLUSIONS:
|
Authors | Alexander Kreuter, Anna Sommer, Julia Hyun, Matthias Bräutigam, Norbert H Brockmeyer, Peter Altmeyer, Thilo Gambichler |
Journal | Archives of dermatology
(Arch Dermatol)
Vol. 142
Issue 9
Pg. 1138-43
(Sep 2006)
ISSN: 0003-987X [Print] United States |
PMID | 16983001
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents
- Calcineurin Inhibitors
- Immunosuppressive Agents
- calcipotriene
- pimecrolimus
- Betamethasone
- Peptidylprolyl Isomerase
- Calcitriol
- Tacrolimus
|
Topics |
- Administration, Cutaneous
- Adult
- Aged
- Aged, 80 and over
- Anti-Inflammatory Agents
(administration & dosage, therapeutic use)
- Betamethasone
(administration & dosage, therapeutic use)
- Calcineurin Inhibitors
- Calcitriol
(administration & dosage, analogs & derivatives, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Immunosuppressive Agents
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Peptidylprolyl Isomerase
(antagonists & inhibitors)
- Psoriasis
(drug therapy, pathology)
- Severity of Illness Index
- Tacrolimus
(administration & dosage, analogs & derivatives, therapeutic use)
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|